Related Experiment Video
Updated: Jul 15, 2025
Experimental Model to Evaluate Resolution of Pneumonia
Published on: February 17, 2023
CNP-miR146a Decreases Inflammation in Murine Acute Infectious Lung Injury
Alyssa E Vaughn1, Tanner Lehmann1, Christina Sul2
1Laboratory for Fetal and Regenerative Biology, Department of Surgery, University of Colorado Denver and Children's Hospital Colorado, Aurora, CO 80045, USA.
Abstract:
Acute respiratory distress syndrome (ARDS) has approximately 40% in-hospital mortality, and treatment is limited to supportive care. Pneumonia is the underlying etiology in many cases with unrestrained inflammation central to the pathophysiology. We have previously shown that CNP-miR146a, a radical scavenging cerium oxide nanoparticle (CNP) conjugated to the anti-inflammatory microRNA(miR)-146a, reduces bleomycin- and endotoxin-induced acute lung injury (ALI) by decreasing inflammation. We therefore hypothesized that CNP-miR146a would decrease inflammation in murine infectious ALI. Mice were injured with intratracheal (IT) MRSA or saline followed by treatment with IT CNP-miR146a or saline control. Twenty-four hours post-infection, bronchoalveolar lavage fluid (BALF) and whole lungs were analyzed for various markers of inflammation. Compared to controls, MRSA infection significantly increased proinflammatory gene expression (IL-6, IL-8, TNFα, IL-1β; p < 0.05), BALF proinflammatory cytokines (IL-6, IL-8, TNFα, IL-1β; p < 0.01), and inflammatory cell infiltrate (p = 0.03). CNP-miR146a treatment significantly decreased proinflammatory gene expression (IL-6, IL-8, TNFα, IL-1β; p < 0.05), bronchoalveolar proinflammatory protein leak (IL-6, IL-8, TNFα; p < 0.05), and inflammatory infiltrate (p = 0.01). CNP-miR146a decreases inflammation and improves alveolar-capillary barrier integrity in the MRSA-infected lung and has significant promise as a potential therapeutic for ARDS.
Insights
Cerium oxide nanoparticles conjugated with microRNA-146a (CNP-miR146a) effectively reduced inflammation and improved lung barrier integrity in a mouse model of bacterial pneumonia, offering a promising new therapy for acute respiratory distress syndrome (ARDS).
Area of Science:
- Biomedical Engineering
- Nanomedicine
- Pulmonary Medicine
Background:
- Acute respiratory distress syndrome (ARDS) has high mortality and limited treatments, often stemming from pneumonia-driven inflammation.
- Existing therapies for ARDS are primarily supportive, highlighting the need for novel anti-inflammatory interventions.
- Previous research demonstrated CNP-miR146a's efficacy in reducing inflammation in non-infectious lung injury models.
Purpose of the Study:
- To investigate the therapeutic potential of CNP-miR146a in reducing inflammation in a murine model of infectious acute lung injury (ALI) caused by MRSA.
- To evaluate the impact of CNP-miR146a on key inflammatory markers and alveolar-capillary barrier integrity in MRSA-induced ALI.
Main Methods:
- Mice were subjected to intratracheal (IT) instillation of MRSA or saline.
- Animals received IT treatment with either CNP-miR146a or saline as a control.
- Inflammatory markers, gene expression, cytokine levels, and cellular infiltration in bronchoalveolar lavage fluid (BALF) and lung tissue were analyzed 24 hours post-infection.
Main Results:
- MRSA infection significantly elevated pro-inflammatory gene expression (IL-6, IL-8, TNFα, IL-1β) and BALF cytokine levels compared to controls.
- CNP-miR146a treatment significantly reduced pro-inflammatory gene expression and BALF cytokine levels in MRSA-infected mice.
- Treatment with CNP-miR146a also decreased inflammatory cell infiltrate and improved alveolar-capillary barrier integrity.
Conclusions:
- CNP-miR146a effectively mitigates inflammation and preserves alveolar-capillary barrier function in a MRSA-induced ALI model.
- These findings suggest CNP-miR146a holds significant promise as a novel therapeutic agent for ARDS.
- Further research is warranted to explore the clinical applicability of CNP-miR146a for ARDS treatment.
